vs

Side-by-side financial comparison of CSW INDUSTRIALS, INC. (CSW) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

CSW INDUSTRIALS, INC. is the larger business by last-quarter revenue ($233.0M vs $151.7M, roughly 1.5× Tarsus Pharmaceuticals, Inc.). CSW INDUSTRIALS, INC. runs the higher net margin — 4.4% vs -5.5%, a 9.9% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 20.3%). CSW INDUSTRIALS, INC. produced more free cash flow last quarter ($22.7M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 5.1%).

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

CSW vs TARS — Head-to-Head

Bigger by revenue
CSW
CSW
1.5× larger
CSW
$233.0M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+108.1% gap
TARS
128.4%
20.3%
CSW
Higher net margin
CSW
CSW
9.9% more per $
CSW
4.4%
-5.5%
TARS
More free cash flow
CSW
CSW
$9.8M more FCF
CSW
$22.7M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
5.1%
CSW

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CSW
CSW
TARS
TARS
Revenue
$233.0M
$151.7M
Net Profit
$10.3M
$-8.4M
Gross Margin
39.7%
Operating Margin
7.4%
-5.3%
Net Margin
4.4%
-5.5%
Revenue YoY
20.3%
128.4%
Net Profit YoY
-61.9%
63.8%
EPS (diluted)
$0.62
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSW
CSW
TARS
TARS
Q4 25
$233.0M
$151.7M
Q3 25
$277.0M
$118.7M
Q2 25
$263.6M
$102.7M
Q1 25
$230.5M
$78.3M
Q4 24
$193.6M
$66.4M
Q3 24
$227.9M
$48.1M
Q2 24
$226.2M
$40.8M
Q1 24
$210.9M
$27.6M
Net Profit
CSW
CSW
TARS
TARS
Q4 25
$10.3M
$-8.4M
Q3 25
$40.7M
$-12.6M
Q2 25
$40.9M
$-20.3M
Q1 25
$35.1M
$-25.1M
Q4 24
$26.9M
$-23.1M
Q3 24
$36.1M
$-23.4M
Q2 24
$38.6M
$-33.3M
Q1 24
$31.8M
$-35.7M
Gross Margin
CSW
CSW
TARS
TARS
Q4 25
39.7%
Q3 25
43.0%
Q2 25
43.8%
Q1 25
44.2%
Q4 24
41.4%
Q3 24
45.6%
Q2 24
47.5%
Q1 24
44.4%
Operating Margin
CSW
CSW
TARS
TARS
Q4 25
7.4%
-5.3%
Q3 25
20.5%
-12.2%
Q2 25
20.8%
-21.6%
Q1 25
19.5%
-33.5%
Q4 24
15.3%
-36.8%
Q3 24
22.6%
-52.3%
Q2 24
24.3%
-81.6%
Q1 24
21.0%
-136.5%
Net Margin
CSW
CSW
TARS
TARS
Q4 25
4.4%
-5.5%
Q3 25
14.7%
-10.6%
Q2 25
15.5%
-19.8%
Q1 25
15.2%
-32.1%
Q4 24
13.9%
-34.8%
Q3 24
15.8%
-48.7%
Q2 24
17.1%
-81.6%
Q1 24
15.1%
-129.4%
EPS (diluted)
CSW
CSW
TARS
TARS
Q4 25
$0.62
$-0.17
Q3 25
$2.41
$-0.30
Q2 25
$2.43
$-0.48
Q1 25
$2.05
$-0.64
Q4 24
$1.60
$-0.57
Q3 24
$2.26
$-0.61
Q2 24
$2.47
$-0.88
Q1 24
$2.03
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSW
CSW
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$40.2M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$1.1B
$343.4M
Total Assets
$2.3B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSW
CSW
TARS
TARS
Q4 25
$40.2M
$417.3M
Q3 25
$31.5M
$401.8M
Q2 25
$38.0M
$381.1M
Q1 25
$225.8M
$407.9M
Q4 24
$213.8M
$291.4M
Q3 24
$273.2M
$317.0M
Q2 24
$18.9M
$323.6M
Q1 24
$22.2M
$298.5M
Total Debt
CSW
CSW
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$800.1M
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$166.0M
$29.9M
Stockholders' Equity
CSW
CSW
TARS
TARS
Q4 25
$1.1B
$343.4M
Q3 25
$1.1B
$335.1M
Q2 25
$1.1B
$332.6M
Q1 25
$1.1B
$342.5M
Q4 24
$1.0B
$224.5M
Q3 24
$1.0B
$237.5M
Q2 24
$650.2M
$252.2M
Q1 24
$615.7M
$275.2M
Total Assets
CSW
CSW
TARS
TARS
Q4 25
$2.3B
$562.2M
Q3 25
$1.5B
$534.6M
Q2 25
$1.5B
$495.0M
Q1 25
$1.4B
$500.8M
Q4 24
$1.4B
$377.0M
Q3 24
$1.4B
$376.3M
Q2 24
$1.1B
$376.8M
Q1 24
$1.0B
$349.3M
Debt / Equity
CSW
CSW
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.75×
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.27×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSW
CSW
TARS
TARS
Operating Cash FlowLast quarter
$28.9M
$19.3M
Free Cash FlowOCF − Capex
$22.7M
$13.0M
FCF MarginFCF / Revenue
9.8%
8.6%
Capex IntensityCapex / Revenue
2.6%
4.2%
Cash ConversionOCF / Net Profit
2.81×
TTM Free Cash FlowTrailing 4 quarters
$162.0M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSW
CSW
TARS
TARS
Q4 25
$28.9M
$19.3M
Q3 25
$61.8M
$18.3M
Q2 25
$60.6M
$-29.4M
Q1 25
$27.3M
$-20.7M
Q4 24
$11.6M
$-22.2M
Q3 24
$66.8M
$-8.7M
Q2 24
$62.7M
$-14.4M
Q1 24
$22.4M
$-37.8M
Free Cash Flow
CSW
CSW
TARS
TARS
Q4 25
$22.7M
$13.0M
Q3 25
$58.7M
$16.3M
Q2 25
$57.7M
$-30.4M
Q1 25
$22.8M
$-21.2M
Q4 24
$8.5M
$-22.3M
Q3 24
$61.3M
$-8.9M
Q2 24
$59.6M
$-15.4M
Q1 24
$17.5M
$-38.0M
FCF Margin
CSW
CSW
TARS
TARS
Q4 25
9.8%
8.6%
Q3 25
21.2%
13.8%
Q2 25
21.9%
-29.6%
Q1 25
9.9%
-27.1%
Q4 24
4.4%
-33.5%
Q3 24
26.9%
-18.6%
Q2 24
26.3%
-37.8%
Q1 24
8.3%
-137.5%
Capex Intensity
CSW
CSW
TARS
TARS
Q4 25
2.6%
4.2%
Q3 25
1.1%
1.6%
Q2 25
1.1%
1.0%
Q1 25
2.0%
0.8%
Q4 24
1.6%
0.1%
Q3 24
2.4%
0.6%
Q2 24
1.4%
2.5%
Q1 24
2.3%
0.6%
Cash Conversion
CSW
CSW
TARS
TARS
Q4 25
2.81×
Q3 25
1.52×
Q2 25
1.48×
Q1 25
0.78×
Q4 24
0.43×
Q3 24
1.85×
Q2 24
1.62×
Q1 24
0.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSW
CSW

Contractor Solutions Segment$166.3M71%
Specialized Reliability Solutions Segment$38.2M16%
Engineered Building Solutions Segment$28.5M12%

TARS
TARS

Segment breakdown not available.

Related Comparisons